Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Olutasidenib,Decitabine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® for mIDH1 AML
Details : Decitabine and venetoclax in combination with Rezlidhia (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Olutasidenib,Decitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CONNECT
Deal Size : $3.0 million
Deal Type : Collaboration
Rigel Collaborates with CONNECT for Olutasidenib Phase 2 Trial in Glioma
Details : The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide for treating high-grade glioma harboring an IDH1 mutation.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Olutasidenib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CONNECT
Deal Size : $3.0 million
Deal Type : Collaboration
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Kissei Pharmaceutical
Deal Size : $162.5 million
Deal Type : Licensing Agreement
Rigel Expands REZLIDHIA® Partnership with Kissei for Japan, Korea, Taiwan
Details : The agreement aims to develop and commercialize Rezlidhia (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
March 09, 2024
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Kissei Pharmaceutical
Deal Size : $162.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
Details : Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1...
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1...
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2022
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Optime Care
Deal Size : Undisclosed
Deal Type : Partnership
Details : Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : Olutasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Optime Care
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-2102 (olutasidenib), is an oral, small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes,in patients with relapsed/refractory acute myeloid leukemia.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Product Name : Rezlidhia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2022
Lead Product(s) : Olutasidenib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and ...
Product Name : FT-2102
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
February 08, 2022
Lead Product(s) : Olutasidenib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Rigel Pharmaceuticals
Deal Size : $235.0 million
Deal Type : Licensing Agreement